drugset / Trial / NCT00057720
TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
RandomizedOpen-labelTreatment
Summary
The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.
Timeline
- Start
- 2003-06
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Topotecan | Small molecule | — | — |
| Subject | canfosfamide | Small molecule | — | — |